Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
Can Revolution Medicines Be a Game-Changer Stock?
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case
Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
Small-Cap ETF Showdown: Schwab's SCHA vs. iShares' IJR
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
US FDA authorizes early access to Revolution's pancreatic cancer pill
Which Is the Better Small-Cap ETF, Vanguard's VB or iShares' ISCB?
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
Vanguard vs. Schwab: Which Small-Cap ETF Belongs in Your Portfolio?
Schwab Small Cap ETF Tops State Street in Returns and Diversification
There's a Revolution in Cancer. But Can Big Pharma Afford It?
Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems
SPSM Offers Lower Costs and Higher Yield Than ISCB
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
Two experimental drugs showed striking early results against pancreatic cancer
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Mark Goldsmith Sells 120,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines (RVMD) Hits All-Time Highs After Groundbreaking Cancer Trial Results
How This Biotech Stock Skirted Today's Selloff
Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough
Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo